Evidence map›Paper›PMID 42379822›Full record

ArticleMicrobiology spectrum2026

High-throughput screening system for antimycobacterial compounds using

Takemasa Takii, Aoi Kimishima, Masato Iwatsuki, Yoshihiro Watanabe, Naoya Ohara, Yukihiro Asami

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takemasa TakiiDepartment of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose, Tokyo, Japan.ORCID 0000-0002-5005-0941
Aoi KimishimaŌmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0002-2625-1356
Masato IwatsukiŌmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0001-8373-4314
Yoshihiro WatanabeŌmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0002-5756-0530
Naoya OharaDepartment of Oral Microbiology, Graduate School of Medicine, Density and Pharmaceutical Sciences, Okayama University, Kita-ku, Okayama, Japan.ORCID 0000-0003-3486-2373
Yukihiro AsamiŌmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.ORCID 0000-0003-1821-9169

Funding

Japan Agency for Medical Research and Development JP21am0101096Japan Agency for Medical Research and Development JP21fk0108590Japan Agency for Medical Research and Development JP22am9121035Japan Agency for Medical Research and Development JP23fk0108591Japan Society for the Promotion of Science 20K07125Japan Society for the Promotion of Science 24K09872
6 · The paper itself

Abstract

The global increase in multidrug-resistant tuberculosis strains poses a major threat; consequently, there is an urgent need to identify and develop novel drugs. We have previously presented a simple fibroblast assay (SFA) screening method that enables the simultaneous assessment of antibacterial activity and cytotoxicity toward host cells. This method was developed based on our finding that live (but not dead) IMPORTANCE: This screening system, comprising the simple fibroblast assay (SFA) and broth dilution test (BDT), effectively identifies low-cytotoxicity compounds that exhibit antimycobacterial activity inside or outside the host cells.

Indexed as

Anti-Bacterial AgentsAntitubercular AgentsBiological ProductsHigh-Throughput Screening AssaysMycobacterium tuberculosisCell LineDrug Evaluation, PreclinicalFibroblastsHumansMicrobial Sensitivity TestsTuberculosisAnti-Bacterial AgentsAntitubercular AgentsBiological Productsantibacterial activityfibroblastsMycobacterium abscessusMycobacterium aviumMycobacterium tuberculosisthe Ōmura Natural Compound Library

Identifiers

PMID42379822
PMCPMC13436251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.